{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:53:20Z","timestamp":1772816000938,"version":"3.50.1"},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1996,3]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> To review critically the literature regarding effects of estrogen replacement therapy (ERT)\/combined estrogen and progesterone replacement therapy (HRT) on the risk of breast cancer and on other health risks and benefits in postmenopausal women, with a focus on risks and benefits in women with a previous diagnosis of breast cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHOD<\/jats:title><jats:p> A literature search was conducted using Medline, Cancerline, and the bibliographies of reports published as of March 1995. All five published meta-analyses that examined the risk of breast cancer in relation to ERT\/HRT in otherwise healthy women were critically reviewed. All known reports of women with a history of breast cancer given ERT\/HRT subsequent to diagnosis and additional reports regarding the benefits of ERT\/HRT were also reviewed. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> None of the five meta-analyses demonstrated a significantly increased risk of developing breast cancer in ever users compared with never users of ERT\/HRT. Current use may be associated with a small increased risk. This increased risk should be balanced by the expected benefits of ERT\/HRT on quality of life, bone metabolism, and cardiovascular function. Preliminary information does not suggest a major detrimental effect of ERT\/HRT in women with a previous diagnosis of breast cancer, but these reports include few women with limited follow-up data. There are no randomized trials in women with a previous diagnosis of breast cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> In healthy postmenopausal women, the benefits associated with ERT\/HRT outweigh the risks. In women with a previous diagnosis of breast cancer, the balance of risks and benefits should be explored in randomized controlled trials. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.1996.14.3.997","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:47:02Z","timestamp":1487929622000},"page":"997-1006","source":"Crossref","is-referenced-by-count":33,"title":["Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?"],"prefix":"10.1200","volume":"14","author":[{"given":"J A","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C A","family":"Sawka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K I","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1996.14.3.997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:06:23Z","timestamp":1653516383000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1996.14.3.997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,3]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,3]]}},"alternative-id":["10.1200\/JCO.1996.14.3.997"],"URL":"https:\/\/doi.org\/10.1200\/jco.1996.14.3.997","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,3]]}}}